Intellia Therapeutics (NTLA) Stock Price, Quote, News & History | Benzinga

Intellia Therapeutics Inc (NTLA) Stock Price, Quote, News & History

NTLANASDAQ

Trade with Public

Trade with Public

$12.84

0.403.22%

At close: Aug 20, 5:00 PM EST

$12.85

0.413.3%

Pre-Market: 8:53 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$12.84

Volume / Avg.

60.66K / 4.93M

Day Range

- - -

52 Wk Range

7.95 - 28.25

Market Cap

$1.80B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

39.57%

Days to Cover

11.96

Recent INTELLIA THERAPEUTICS, INC. News

This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pharmaceuticals. See what other analysts say.

Avi Kapoor

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.

Vandana Singh

Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)

Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpark.

Erica Kollmann

Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% after beating earnings & revenue estimates. Other big gainers included QURE, CLPT, JLHL, BRAI, LZB, HQ, SHAZ, WNC, RXT, ARQQ, and MFI.

Avi Kapoor

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and reinforced its regulatory outlook.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-346.64M

Investing Cash Flow (TTM)

-48.47M

Financing Cash Flow (TTM)

346.52M

Free Cash Flow (TTM)

-348.69M

Capital Expenditure (TTM)

-2.04M

Net Change in Cash (TTM)

-48.59M

Analyst Trends and Forecast

2

2

1

Apr

2

2

May

2

1

Jun

1

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.3

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.43B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

25.80

PB Ratio (TTM)

2.47

Earnings Yield % (TTM)

-26.02%

Earnings Yield % (FWD)

-23.84%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$5.19

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$106.13M

Debt to Equity

0.10

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$12.84

Volume / Avg.

60.66K / 4.93M

Day Range

- - -

52 Wk Range

7.95 - 28.25

Market Cap

$1.80B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

39.57%

Days to Cover

11.96

About

Sector

Health Care

Industry

Biotechnology

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a rev...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Intellia Therapeutics (NTLA) stock?

A

You can purchase shares of Intellia Therapeutics (NASDAQ:NTLA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Intellia Therapeutics (NTLA) competitors?

A

Other companies in Intellia Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Intellia Therapeutics (NTLA) stock?

A

Intellia Therapeutics has a consensus price target of $25.43.

Q

What is the current price for Intellia Therapeutics (NTLA)?

A

The stock price for Intellia Therapeutics (NASDAQ: NTLA) is $12.85 last updated August 24, 2026 at 8:38 AM EDT.

Q

Does Intellia Therapeutics (NTLA) pay a dividend?

A

There are no upcoming dividends for Intellia Therapeutics.

Q

When is Intellia Therapeutics (NASDAQ:NTLA) reporting earnings?

A

Intellia Therapeutics does not have any upcoming earnings scheduled.

Q

Is Intellia Therapeutics (NTLA) going to split?

A

There is no upcoming split for Intellia Therapeutics.

Q

What sector and industry does Intellia Therapeutics (NTLA) operate in?

A

Intellia Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.